INDO US BIO-TECH LTD.

NSE : NABSE : 541304ISIN CODE : INE250Z01010Industry : AgricultureHouse : Private
BSE216.050 (0 %)
PREV CLOSE ( ) 216.05
OPEN PRICE ( ) 231.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 3000
TODAY'S LOW / HIGH ( )215.10 231.00
52 WK LOW / HIGH ( ) 90.1303.95
NSE
This Company is not listed in NSE
( in Million)
Select year
ParticularsMar2022Mar2021Mar2020
Profit Before Tax53.1139.2928.64
Adjustment16.4014.3110.98
Changes In working Capital-38.61-50.65-47.75
Cash Flow after changes in Working Capital30.902.96-8.13
Cash Flow from Operating Activities27.031.58-8.43
Cash Flow from Investing Activities-54.42-17.79-5.67
Cash Flow from Financing Activities26.5415.5515.28
Net Cash Inflow / Outflow-0.85-0.661.18
Opening Cash & Cash Equivalents1.342.000.82
Cash & Cash Equivalent on Amalgamation / Take over / MergerNANANA
Cash & Cash Equivalent of Subsidiaries under liquidationsNANANA
Translation adjustment on reserves / op cash balalces frgn subsidiariesNANANA
Effect of Foreign Exchange FluctuationsNANANA
Closing Cash & Cash Equivalent0.491.342.00

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.